Banca Mediolanum Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Banca Mediolanum's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 13.3% per year. EPS is expected to decline by 1.3% per annum. Return on equity is forecast to be 20.8% in 3 years.
Wichtige Informationen
-1.9%
Wachstumsrate der Gewinne
-1.3%
EPS-Wachstumsrate
Diversified Financial Gewinnwachstum | 31.0% |
Wachstumsrate der Einnahmen | 13.3% |
Zukünftige Eigenkapitalrendite | 20.8% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 01 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
If EPS Growth Is Important To You, Banca Mediolanum (BIT:BMED) Presents An Opportunity
Sep 09Banca Mediolanum S.p.A. (BIT:BMED) Just Released Its Interim Earnings: Here's What Analysts Think
Aug 04Is Now The Time To Put Banca Mediolanum (BIT:BMED) On Your Watchlist?
May 03Banca Mediolanum (BIT:BMED) Will Pay A Larger Dividend Than Last Year At €0.42
Mar 11Should You Be Adding Banca Mediolanum (BIT:BMED) To Your Watchlist Today?
Jan 28Banca Mediolanum (BIT:BMED) Has Affirmed Its Dividend Of €0.24
Nov 13Here's Why We Think Banca Mediolanum (BIT:BMED) Is Well Worth Watching
Aug 10I Ran A Stock Scan For Earnings Growth And Banca Mediolanum (BIT:BMED) Passed With Ease
Apr 08Here's Why We Think Banca Mediolanum (BIT:BMED) Is Well Worth Watching
Dec 21New Forecasts: Here's What Analysts Think The Future Holds For Banca Mediolanum S.p.A. (BIT:BMED)
Feb 15How Many Banca Mediolanum S.p.A. (BIT:BMED) Shares Did Insiders Buy, In The Last Year?
Jan 31If You Had Bought Banca Mediolanum's (BIT:BMED) Shares A Year Ago You Would Be Down 21%
Dec 28Here's Why I Think Banca Mediolanum (BIT:BMED) Is An Interesting Stock
Nov 23Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 3,145 | 869 | 835 | N/A | 2 |
12/31/2025 | 3,061 | 880 | 848 | N/A | 3 |
12/31/2024 | 2,980 | 901 | 872 | N/A | 3 |
6/30/2024 | 2,066 | 908 | 581 | 631 | N/A |
3/31/2024 | 1,984 | 864 | N/A | N/A | N/A |
12/31/2023 | 1,870 | 822 | -1,806 | -1,754 | N/A |
9/30/2023 | 1,712 | 702 | N/A | N/A | N/A |
6/30/2023 | 1,587 | 629 | 132 | 200 | N/A |
3/31/2023 | 1,468 | 571 | N/A | N/A | N/A |
12/31/2022 | 1,377 | 507 | 2,239 | 2,298 | N/A |
9/30/2022 | 1,585 | 714 | N/A | N/A | N/A |
6/30/2022 | 1,547 | 685 | 1,034 | 1,093 | N/A |
3/31/2022 | 1,585 | 694 | N/A | N/A | N/A |
12/31/2021 | 1,599 | 713 | 848 | 909 | N/A |
9/30/2021 | 1,425 | 560 | N/A | N/A | N/A |
6/30/2021 | 1,408 | 553 | 81 | 119 | N/A |
3/31/2021 | 1,310 | 496 | N/A | N/A | N/A |
12/31/2020 | 1,215 | 434 | -18 | 24 | N/A |
9/30/2020 | 1,457 | 531 | N/A | N/A | N/A |
6/30/2020 | 1,445 | 545 | 162 | 192 | N/A |
3/31/2020 | 1,470 | 566 | N/A | N/A | N/A |
12/31/2019 | 1,469 | 565 | 328 | 363 | N/A |
9/30/2019 | 1,038 | 268 | N/A | N/A | N/A |
6/30/2019 | 1,012 | 252 | 257 | 305 | N/A |
3/31/2019 | 1,005 | 268 | N/A | N/A | N/A |
12/31/2018 | 987 | 256 | 312 | 357 | N/A |
9/30/2018 | 1,031 | 373 | 181 | 248 | N/A |
6/30/2018 | 1,006 | 359 | 207 | 278 | N/A |
3/31/2018 | 944 | 355 | N/A | N/A | N/A |
12/31/2017 | 970 | 380 | N/A | 275 | N/A |
9/30/2017 | 938 | 368 | N/A | N/A | N/A |
6/30/2017 | 983 | 420 | N/A | -789 | N/A |
3/31/2017 | 1,007 | 405 | N/A | N/A | N/A |
12/31/2016 | 985 | 394 | N/A | -849 | N/A |
9/30/2016 | 1,068 | 432 | N/A | N/A | N/A |
6/30/2016 | 1,014 | 382 | N/A | 155 | N/A |
3/31/2016 | 1,009 | 374 | N/A | N/A | N/A |
12/31/2015 | 1,103 | 439 | N/A | -7,651 | N/A |
12/31/2013 | 868 | 188 | N/A | -454 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BMED's earnings are forecast to decline over the next 3 years (-1.9% per year).
Ertrag vs. Markt: BMED's earnings are forecast to decline over the next 3 years (-1.9% per year).
Hohe Wachstumserträge: BMED's earnings are forecast to decline over the next 3 years.
Einnahmen vs. Markt: BMED's revenue (13.3% per year) is forecast to grow faster than the Italian market (3.9% per year).
Hohe Wachstumseinnahmen: BMED's revenue (13.3% per year) is forecast to grow slower than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BMED's Return on Equity is forecast to be high in 3 years time (20.8%)